Literature DB >> 7974631

Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography.

S Härtter1, B Hermes, A Szegedi, C Hiemke.   

Abstract

An automated column-switching method coupled to isocratic high-performance liquid chromatography has been developed for simultaneous determination of blood levels of paroxetine and its nonconjugated main metabolite BRL 36610. The lower limits of detection were 9-15 nmol/L (3-5 ng/ml) and linearity between drug concentration and detector response was found for 0-1,500 nmol/L (0-500 ng/ml). The method could be applied to the analysis of serum samples obtained from depressed patients who were treated with daily oral doses of 20 or 40 mg of paroxetine. After the 20-mg dose, the mean blood level of paroxetine was 69 nM (23 ng/ml), whereas the metabolite BRL 36610 was detectable in only one of 5 samples. Co-medication of paroxetine with imipramine increased the blood levels of imipramine, desipramine, and paroxetine thus indicating drug interactions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7974631     DOI: 10.1097/00007691-199408000-00011

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

Review 1.  Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C L DeVane
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 2.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

3.  Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.

Authors:  Katja Grasmäder; Petra Louise Verwohlt; Marcella Rietschel; Aleksandra Dragicevic; Matthias Müller; Christoph Hiemke; Nikolaus Freymann; Astrid Zobel; Wolfgang Maier; Marie Luise Rao
Journal:  Eur J Clin Pharmacol       Date:  2004-05-28       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.